

RECEIVED
CENTRAL FAX CENTER**OCT 12 2005**

Telephone 617-428-0200

Facsimile 617-428-7045

617-428-7046

101 Federal Street
Boston, MA 02110**Clark & Elbing LLP****Date:** October 12, 2005**To:** Examiner David Lukton
U.S. Patent and Trademark Office
Group Art Unit 1653**Facsimile No.:** 571-273-8300**From:** Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109**Re:** U.S. Patent Application Serial No. 09/341,590
PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES
HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC
HYDROLYSIS

Larsen

Filed: July 12, 1999

Attorney Docket No.: 50412/008001

Customer No. 21559

Pages: 3, including cover page.**Message:** The following papers are enclosed:

Revocation and New Power of Attorney (2 pages)

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

BEST AVAILABLE COPY

RECEIVED
CENTRAL FAX CENTER

OCT 12 2005

PATENT

ATTORNEY DOCKET NO. 50412/008001

Certificate of Facsimile Transmission: Date of Transmission: 10-12-05

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450; Facsimile No. 571-273-8300.

JANET D'ANNUNZIO-ELLIS
Printed Name of Person Faxing Transmission

Janet D'Annunzio-Ellis
Signature of Person Faxing Transmission

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Bjarne Due Larsen	Art Unit:	1653
Serial No.:	09/341,590	Examiner:	David Lukton
Filed:	July 12, 1999	Customer No.:	21559
Title:	PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Zealand Pharma A/S, a corporation, certifies that it is the assignee of 100% of the right, title, and interest in the patent application identified above by virtue of:

A chain of title from the inventor to the current assignee as shown below. Copies of the assignments or other documents in the chain of title are enclosed.

1. From Inventor Bjarne Due Larsen to Zealand Pharmaceuticals A/S, as recorded in the Patent and Trademark Office at Reel 010458, Frame 0498, on July 13, 1999.
2. From Zealand Pharmaceuticals A/S to Zealand Pharma A/S, as recorded in the Patent and Trademark Office at Reel 013152, Frame 0784, on August

BEST AVAILABLE COPY

5, 2002.

The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney previously granted in the application and appoints the attorneys and/or agents of Clark & Elbing LLP, associated with customer number 21559, with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.


All correspondence regarding the application should be sent to the address associated with customer number 21559.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Date:

11/10/06

Respectfully submitted,



Zealand Pharma A/S

Eva STEWESS
CED

BEST AVAILABLE COPY